RecruitingPhase 2NCT05478707

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Sponsor

AdventHealth Translational Research Institute

Enrollment

47 participants

Start Date

Oct 5, 2023

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 1 Endothelial Dysfunction

Summary

The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dulaglutide and a drug called Placebo for people with diabetes mellitus, type 1 and endothelial dysfunction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDulaglutide

GLP1-RA

DRUGPlacebo

Saline placebo

Locations(1)

AdventHealth Translational Research Institute

Orlando, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05478707

Related Trials

Changes in Person-reported Outcomes and Behavior Using the Accu-Chek SmartGuide CGM and Predict App

NCT07814508

Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research

NCT032537051 location

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332136 locations

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137110 locations

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT0478626229 locations